NCT06104215 is a EARLY_PHASE1 clinical trial of BGT007H Injection in Digestive Tract Cancer, sponsored by The Affiliated Hospital of Xuzhou Medical University.

Who is sponsoring NCT06104215?

NCT06104215 is sponsored by The Affiliated Hospital of Xuzhou Medical University.

What drugs are being tested in NCT06104215?

Interventions in NCT06104215: BGT007H Injection.

What condition does NCT06104215 study?

NCT06104215 studies Digestive Tract Cancer.

Is NCT06104215 still recruiting?

NCT06104215 is currently recruiting now. Last updated 27 October 2023.

Last reviewed 2023-10-27 · How we verify

NCT06104215

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BGT007H Cells for the Treatment of Refractory Digestive System Tumors

Recruiting now EARLY_PHASE1 Last updated 27 October 2023

What this trial tests

EARLY_PHASE1 trial testing BGT007H Injection in Digestive Tract Cancer in 14 participants. Currently enrolling.

Timeline

22 October 2023

Primary endpoint
20 October 2026

20 October 2027

Quick facts

Lead sponsor	The Affiliated Hospital of Xuzhou Medical University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	22 October 2023
Primary completion	20 October 2026
Estimated completion	20 October 2027
Sites	1 location across China

Drugs / interventions tested

BGT007H Injection — full drug profile →

Conditions studied

Digestive Tract Cancer — all drugs for Digestive Tract Cancer →

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Who can join

Adults 18 to 70, any sex, with Digestive Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The Affiliated Hospital of Xuzhou Medical University trials

Trials by the same sponsor.

NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06104215 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
Last refreshed: 27 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing